Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV

Major Program
US-Latin American-Caribbean U54
Sponsor
Weill Medical College of Cornell University
Status
Active, not recruiting
NCT ID
NCT04255849
This is a randomized, double-blinded, placebo-controlled Phase III interventional trial of the nine-valent HPV vaccine (9vHPV) to prevent persistent oral HPV infection in adult men living with HIV.
Intervention
9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Saline Placebo
Condition
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection, HPV Infection
Investigators
Grant Ellsworth, MD, MS

See list of participating sites